Recent Updates
Recently added Catalysts

Verdiperstat

Phase 2

Amyotrophic Lateral Sclerosis | Small molecule | Neurology |Merit Medical Systems, Inc.|Last Updated: Jun 12, 2023

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment167
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04436510HEALEY ALS Platform Trial - Regimen B VerdiperstatPHASE2 COMPLETED 167Jul 28, 2020Dec 6, 2022Jun 12, 20231 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Disease Progression as Assessed by the ALSFRS-R-Slope
Baseline to 24 Weeks

Change in disease severity as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) total score using a Bayesian repeated measures model that accounts for loss to follow-up due to mortality. Each of 12 questions assessing distinct functional ability is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.

Mortality Even Rate
Baseline to 24 Weeks

Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The rate of mortality was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times.

Secondary Endpoints
Respiratory Function
Baseline to 24 Weeks
Muscle Strength
Baseline to 24 Weeks
Number of Participants That Experienced Death or Death Equivalent
24 Weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
VerdiperstatEXPERIMENTALVerdiperstat is administered twice daily p.o. for 24 weeks.
Matching PlaceboPLACEBO_COMPARATORMatching placebo is administered twice daily p.o. for 24 weeks.
Interventions
NameTypeDescription
Matching PlaceboDRUGDrug: Matching Placebo Administration: Oral Dose: two tablets twice daily
VerdiperstatDRUGDrug: Verdiperstat Administration: Oral Dose: 600mg twice daily
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683). Exclusion Criteria: * The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683). 1. Parti...

Countries:United States
Unlock Eligibility Criteria